Member Contact: Dr Leearne Hinch
Position: Chief Executive Officer
Industry: Biotech & Pharmaceuticals
BARD1 Life Sciences Ltd (ASX:BD1) is a leading Australian-based medical diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on the development and commercialisation of best in class lifesaving diagnostic solutions for health care professionals and patients. The cancer diagnostics portfolio includes the marketed hTERT ICC test (an adjunctive urine cytology test) to aid in the diagnostic assessment of bladder cancer with additional diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers.